Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Discover how AI transforms eye care with innovative tools for managing age-related macular degeneration, enhancing treatment efficiency and patient outcomes.

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Advertorial: Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy? The triad of inflammation, neuropathy, and vasculopathy plays a key role ...

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova with an untreated control group for the treatment of X-linked retinitis pigmentosa (XLRP).